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Abstract 
Prostate cancer is the most common cancer in men accounting for around 24% of all 
male cancers in UK. The role of chemotherapy in the neoadjuvant and adjuvant 
setting is still unclear despite considerable progress in this area. Chemotherapy for 
advanced prostate cancer has become the standard of care however options of 
treatment following taxotere failure are still limited. This review summarises recent 
advances in chemotherapy treatment options for early as well as advanced prostate 
cancer.  
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Introduction 
Prostate cancer remains the most common cancer in men accounting for around 24% 
of all male cancers in UK. The approach to organ-confined disease is gradually 
changing with the emphasis on avoiding unnecessary treatment ‘active surveillance’ 
and the development of local therapies as alternatives to external beam radiotherapy 
and radical prostatectomy. The role of chemotherapy in the neoadjuvant and adjuvant 
setting to accompany any of these options is still unclear despite considerable 
progress in other solid tumours in the same context. The optimism for progress in 
treating organ-confined prostate cancer still has to be tempered by the lack of 
effective options for individuals with hormone refractory prostate cancer. In the last 
few years taxotere chemotherapy has become a standard of care for  HRPC following  
the landmark TAX 327 and SWOG 9916 studies which showed that chemotherapy 
can offer a survival advantage and control cancer related symptoms [1, 2]. Beyond 
taxotere, the patient pathway is very uncertain as no current second line 
chemotherapeutic agent alters the natural history of the disease. There is, therefore, a 
considerable unmet need for a large patient population worldwide, and this is being 
actively addressed by the development of studies with novel chemotherapies 
increasingly in combination with targeted therapies. 
 
Neoadjuvant chemotherapy 
Chemotherapy has been tested in the neoadjuvant context prior to radical 
prostatectomy. Such studies are difficult to evaluate in view of relatively favourable 
prognostic group of patients targeted, endpoints used (PSA, progression free survival 
rather than overall survival) and longevity of the studies. Fears of alteration of 
histological features particularly at resection margins in the post resection tumour 
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have so far been unfounded. The studies invariably extrapolate the treatment approach 
from positive findings from metastatic studies. Of the agents evaluated, taxotere was 
well tolerated and resulted in 81% of patients (with a median follow up of 26.5 
months) showing no recurrence in PSA post prostatectomy.  [3]. Estramustine alone, 
as well as in combination with taxotere may also be active  in this  setting with 71-
84% of patients achieving a biochemical disease-free survival of 9-23months [4]; [5]; 
[6]. A large randomised phase III study of radical prostatectomy alone versus taxotere 
and androgen deprivation before radical prostatectomy (CALGB 90203) for high-risk 
patients is currently ongoing. (www.calgb.org/).  
 
Adjuvant chemotherapy 
Adjuvant chemotherapy is the standard of care after radical surgery in most common 
epithelial cancers such as breast, bowel, lung and ovarian cancer, where it offers a 
survival advantage but is still associated with acceptable toxicity. The difference in 
the prostate cancer context has been the lack of efficacy of a large number of 
chemotherapies in the metastatic setting, unlike in breast and gastrointestinal cancers. 
At the same time, patients at ‘high risk’ with presumed micrometastatic disease may 
be easily identified and targeted for new studies. Previously, the National Prostate 
Cancer Project  compared cyclophosphamide or estramustine with observation after 
radical prostatectomy or radiotherapy and found that the estramustine treated group 
had a significantly longer progression-free survival than the other groups[7]. Adjuvant 
weekly taxotere in patients with high risk prostate cancer after radical prostatectomy 
[8] has been reported recently. At a median follow up of 28 months (range 10.5-38.5), 
the median progression-free survival of 15.7 months was longer than the predicted 10-
month median progression free survival for a matched population.  Two large 
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randomised phase III studies are currently under way: the SWOG 9921 trial compares 
mitoxantrone/prednisolone in addition to 2 years of hormone treatment versus 
hormone treatment alone (www.swog.org). The TAX 3501 study compares taxotere 
in a 4 arm study with immediate versus delayed hormone deprivation therapy. 
 
Chemotherapy for metastatic disease 
Despite the advent of molecular based therapy and antiangiogenic strategies, there has 
been intense activity in evaluating new chemotherapeutic agents in the metastatic 
setting. Satraplatin is a third generation platinum compound, structurally similar to 
cisplatin and orally bio-available [9]. Phase II data showed promising results with 
median survival (MS) of 16.7 months, and median progression-free survival (PFS) of 
7.7months [10]. On the base of the results of this trial, a large phase III trial was 
organised by EORTC. Unfortunately due the problems with the sponsoring company 
the trial recruitment was terminated after only 50 out of 380 patients were enrolled 
[11]. The analysis of the 50 patients showed the median PFS twice as long on the 
satraplatin arm (5.2 versus 2.6 months) and there was a trend towards improved 
overall survival (OS), 14.9 versus 11.9 months. Two further satraplatin studies were 
terminated early (CA142-029 and CA142-026) and there is no data analysis available. 
Satraplatin in second line chemotherapy setting, after taxotere failure, was 
investigated in a SPARC (SatraPlatin Against Refractory Cancers) trial. The 
multicentre phase III study was reported in 2007 [12]. A total of 950 patients were 
accrued. Patients in the satraplatin arm had a 31% reduction in the risk of PFS events 
compared to placebo (HR-0.69 CI:05.-0.8), objective tumour response (7% versus 
1%) and pain response (24% versus 14%). The commonest side effect was 
myelosupression, although grade 4 toxicity was uncommon (4%). Unfortunately the 
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trial did not achieve the endpoint of overall survival. The median survival was 61.3 
weeks for the satraplatin arm compared to 61.4 weeks for the control group and the 
hazard ratio was 0.97 (95% CI 0.83, 1.13). 
A novel class of tubule-polymerising agents, epothilones, has been tested in 
metastatic HRPC. The drugs act by stabilising cellular microtubules inducing mitotic 
arrest, in a similar way to taxanes. They have been shown to be effective in taxane-
sensitive and taxane-resistant tumour cell lines [13]. Epothilones were tested as first 
line treatment for HRPC as well as second line chemotherapy. A phase 2 study of 
Ixabepilone, by South-West Oncology Group showed median PFS of 6 months, 
median survival of 18 months and 39% of patients had a true ( ≥50%, sustained over 2 
readings 4 weeks apart) PSA response [14]. Ixabepilone in combination with 
estramustine showed a 48% objective radiological response in the combination arm 
versus 32% with ixabepilone alone [15] . The PSA response was 69% vs 48% and 
time to PSA-progression was 5.2 versus 4.4 months respectively. Ixabepilone 
following taxotere treatment failure was compared to mitoxantrone [16].  A PSA 
response was seen in 20% of patients treated with mitoxantrone versus 17% on the 
ixabepilone arm; the median survival was 13 and 12 months respectively. Epothilone 
B (patupilone) is also active in patients who had previous taxane therapy and 
associated with a  25% PSA response [17].  
 
Several novel targeted agents have now been used in HRPC in combination with 
chemotherapy or as single agents. One of the most active drugs is atrasentan, an 
endothelin-A receptor antagonist. Endothelin-1 promotes tumour growth and 
progression and may be involved in the development of bone metastases [18]. 
Atrasentan has been subjected to a number of studies: a meta-analysis of the data 
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showed a significantly longer time to disease progression, time to bone pain and time 
to biochemical progression [19]. The eventual utility of atresentan may be in 
combination with other agents such as docetaxel or other chemotherapy agents. 
 
Angiogenesis inhibitors such as bevacizumab have been tested in HRPC in 
combination with taxotere and estramustine. The CALGB 90006 trial showed very 
high responses with 81% of patients achieving a PSA response, as compared to 68% 
in patients treated with taxotere and estramustine alone [20]. In this study, the overall 
median survival was 21 months versus 19 months respectively.  A large phase III 
study CALGB90401 of taxotere and prednisolone with and without bevacizumab is 
currently ongoing.  
Thalidomide as an anti-angiogenic and immunostimulatory agent has undergone 
phase II evaluation in prostate cancer as a single agent RESPONSE + REF. A 
combination of thalidomide and taxotere resulted in 53% PSA response and increased 
median time to disease progression of 5.9 months [21]. The addition of bevacizumab 
to this  combination resulted in higher responses but also high toxicity  [22]. A PSA 
response was reported in 87% of patients but 12.8% had febrile neutropenia and 
several patients had significant toxicities such as syncope, grade 3 bleeding, colon 
perforation or fistula formation and thrombosis. 
Gefitinib, an orally active EGFR tyrosine kinase inhibitor is reported to be moderately 
active in HRPC as a single agent, however the comparison with placebo showed no 
difference in TTP, progression rate or overall survival [23] . In combination with 
Prednisolone it appears to achieve PSA control and  prolongs patients survival 
[24].Eighty two patients were enrolled, median time to death was 26.5months as 
compared with 20.5 months in placebo group.  
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Vitamin D analogues show anti-tumour activity in several prostate cancer models 
[25]. The mode of action is by inhibition of proliferation and cell-cycle arrest, 
induction of apoptosis and reduction of invasiveness and angiogenesis [26], [27], [28]. 
Phase II on data on 26 patients of combination of DN-101 with taxotere in patients 
with HRPC previously treated with taxotere showed that it is a well tolerated and 
active combination [29]. A randomised phase III study of high –dose calcitriol plus 
taxotere versus placebo plus taxotere (ASCENT study) confirmed the above results 
[30] . Overall PSA response rates were 63% (DN101) and 52% (placebo). Grade 3/4 
adverse events were frequent – 58%, but the placebo group recorded 70% rate. The 
analysis showed a trend towards improvement in survival but survival was not a 
primary endpoint. The ASCENT II study comparing survival with weekly or every 3 
weeks doses of docetaxel in combination with DN-101 with standard docetaxel and 
prednisone was closed  due to safety issues and imbalance of deaths between the two 
treatment arms.  
 
Other new drugs that are currently in early phase trials for HRPC include 
Halichondron B Analog-E7389, an antimicrotubule agent and Ispinesib (SB-715992)-
acting on mitotic protein subsequently leading to cell cycle arrest  and cell death. 
 
Various chemotherapy combinations have been tried as a second line treatment but 
none of the options have had any impact on overall survival. Vinorelbine and 
estramustine demonstrated activity and longer median overall survival, the numbers 
of patients treated however were very small [31]. Taxotere in combintaion with 
Carboplatin is also active with PSA responses seen in 18% of patients [32].   
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Chemotherapy with taxotere is now a standard approach for HRPC. However, 
significant numbers of patients progress and are fit for further lines of treatment. No 
single agent has so far made a significant impact following taxotere failure but 
numerous further single agent and combination studies are ongoing. The development 
of molecular or ‘targeted’ therapy called into the question the future of more 
traditional chemotherapeutic strategies. Rather than discarding cytotoxic approaches it 
is most likely their maximum utility will be in combination with targeted therapy. 
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